Sept 28 (Reuters) - OSE IMMUNOTHERAPEUTICS SA: * SIGNS A LICENSE OPTION AGREEMENT WITH INSERM TO DEVELOP A NEW CANCER IMMUNOTHERAPY ...
確定! 回上一頁